<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03835754</url>
  </required_header>
  <id_info>
    <org_study_id>OCS-CAR-121918</org_study_id>
    <nct_id>NCT03835754</nct_id>
  </id_info>
  <brief_title>Heart EXPAND Continued Access Protocol</brief_title>
  <official_title>Heart Expand Continued Access Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TransMedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TransMedics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The OCS™ Heart System will be used to preserve and assess donor hearts that do not meet&#xD;
      current standard donor heart acceptance criteria for transplantation in this continued access&#xD;
      protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To provide additional data evaluating the safety and effectiveness of the OCS™ Heart System&#xD;
      to preserve and assess donor hearts that do not meet current standard donor heart acceptance&#xD;
      criteria (as identified above) for transplantation to potentially improve donor heart&#xD;
      utilization for transplantation at a range of transplant centers in the U.S. and to permit&#xD;
      patients and physicians access to the OCS Heart System while a PMA application is under&#xD;
      preparation and review.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 17, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Actual">September 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>30 days</time_frame>
    <description>Patient survival post transplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of severe PGD</measure>
    <time_frame>24 hours post heart transplant</time_frame>
    <description>Absence of severe primary heart graft dysfunction of left and/or right ventricle in the first 24 hours post transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>30 days</time_frame>
    <description>Patient and graft survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe PGD</measure>
    <time_frame>24 hours post transplant</time_frame>
    <description>Incidence of severe primary heart graft dysfunction of left and/or right ventricle in the first 24 hours post heart transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor heart utilization rate</measure>
    <time_frame>24 hours post-transplant</time_frame>
    <description>The proportion of eligible donor hearts that were successfully transplanted after preservation and assessment on the OCS Heart System</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Survival</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Patient survival at 6 and 12 months post-transplant</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of primary graft failure</measure>
    <time_frame>Through 12 months post transplant</time_frame>
    <description>Incidence of primary graft failure requiring re-transplantation</description>
  </other_outcome>
  <other_outcome>
    <measure>ICU stay</measure>
    <time_frame>Through hospital discharge, estimated to be 14 days</time_frame>
    <description>Duration of initial post-transplant ICU stay in days</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital stay</measure>
    <time_frame>Through hospital discharge, estimated to be 30 days</time_frame>
    <description>Duration of initial post-transplant hospital stay in days</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Heart Transplant</condition>
  <arm_group>
    <arm_group_label>OCS Preservation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCS Heart System</intervention_name>
    <description>The OCS Heart System preserves the heart in a near-physiological, beating state by perfusing the heart with a warmed, donor-blood based perfusate that is supplemented with nutrients and oxygen in a controlled and protected environment</description>
    <arm_group_label>OCS Preservation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (DONOR):&#xD;
&#xD;
        At least one of the following:&#xD;
&#xD;
          -  Expected total cross-clamp time of ≥ 4 hours&#xD;
&#xD;
          -  Expected total cross-clamp time of ≥ 2 hours PLUS one or more of the following risk&#xD;
             factors Donor age 45-55 years, inclusive, with no coronary catheterization data; or&#xD;
             Donor age ≥ 55 years; or Left ventricular septal or posterior wall thickness of &gt;12&#xD;
             mm, but ≤ 16 mm; or Reported down time of ≥ 20 min, with stable hemodynamics at time&#xD;
             of final assessment; or Left heart ejection fraction (EF) ≥ 40%, but ≤ 50% at time of&#xD;
             acceptance of offer; or Donor angiogram with luminal irregularities with no&#xD;
             significant CAD (≤ 50%); or History of carbon monoxide poisoning with good cardiac&#xD;
             function at time of donor assessment; or Social history of alcoholism with good&#xD;
             cardiac function at time of donor assessment; or History of diabetes without&#xD;
             significant CAD (≤ 50%) on angiogram.&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          -  CAD with &gt; 50% stenosis on angiogram, or&#xD;
&#xD;
          -  Cardiogenic shock or myocardial infarction, or&#xD;
&#xD;
          -  EF consistently &lt; 40%, or&#xD;
&#xD;
          -  Significant valve disease except for competent bicuspid aortic valve.&#xD;
&#xD;
        Eligibility Criteria (RECIPIENT)&#xD;
&#xD;
          -  Registered primary heart transplant candidate&#xD;
&#xD;
          -  Age &gt;18 years old&#xD;
&#xD;
          -  Written informed consent. Exclusion&#xD;
&#xD;
          -  Prior solid organ or bone marrow transplant&#xD;
&#xD;
          -  Chronic use of hemodialysis or renal replacement therapy for diagnosis of chronic&#xD;
             renal insufficiency requiring dialysis&#xD;
&#xD;
          -  Multi-organ transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cedars-Sinai</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Cardiovascular Research Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyph/Cumc</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 22, 2019</study_first_submitted>
  <study_first_submitted_qc>February 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2019</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart preservation</keyword>
  <keyword>Beating heart transplant</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

